<?xml version="1.0" encoding="UTF-8" ?><dbgapss xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dbgapssws.1.0.xsd"><Study uid="5456" whole_study_id="5456" phs="000139" v="1" p="1" createDate="2008-11-20T16:05:19-05:00" modDate="2019-07-19T13:30:22-05:00" maxParentChildStudyModDate="2019-07-19T13:30:22-05:00" handle="IMSGC" num_participants="3002"><StudyInfo accession="phs000139.v1.p1" parentAccession="phs000139.v1.p1"><BioProject id="PRJNA75425" entrez_id="75425" type="bp_admin_access"/><BioProject id="PRJNA75427" entrez_id="75427" type="bp_data_submission"/><StudyNameReportPage>http://www.imsgc.org/</StudyNameReportPage><StudyNameEntrez>International Multiple Sclerosis Genomics Consortium (IMSGC) Genome Wide Association Study of Multiple Sclerosis</StudyNameEntrez><StudyTypes2 calculated="Yes"><StudyType21 name="phenotype_data" chosen="Yes"/><StudyType21 name="analysis" chosen="No"/><StudyType21 name="individual_sequencing" chosen="No"/><StudyType21 name="supporting_documents" chosen="No"/><StudyType21 name="images" chosen="No"/><StudyType21 name="molecular" chosen="No"/><StudyType21 name="subject_samples" chosen="Yes"/><StudyType21 name="links_to_ncbi_dbs" chosen="No"/><StudyType21 name="other_general" chosen="No"/></StudyTypes2><StudyTypes><StudyType>phenotype_data</StudyType></StudyTypes><Description>
&lt;p&gt;The goal of this study is to perform a comprehensive allelic and genotypic association analysis of the entire human genome
 in multiple sclerosis.  The recent definitive linkage genome screen demonstrated that there is no other MS risk gene with an
 effect size anywhere near that of the MHC.  However, linkage analysis is significantly hampered by reduced power in the face
 of heterogeneity and requires multiplex families, which also hampers acquiring an appropriate sample size.  In contrast,
 genotyping 500K SNPs allows us to survey a significant amount of the genome (we estimate &gt;70%) directly for allelic
 or genotypic association.  This uses the improved power of association analysis and can also take advantage
 of the linkage disequilibrium relationships among SNPs to further increase power (e.g. haplotype analysis).  Quality control
 and data analysis are significant challenges.  We will initially perform substantial QC checks and analyze the data using both
 TDT and AFBAC approaches.  Multigenic interactions will also be tested using MDR.&lt;/p&gt;
 </Description><Attributions><Header title="Principal Investigators"><AttrName>Alastair Compston, F.Med.Sci, PhD</AttrName><Institution>University of Cambridge School of Clinical Medicine, Cambridge, UK</Institution></Header><Header title="Principal Investigators"><AttrName>Stephen L. Hauser, MD</AttrName><Institution>University of California at San Francisco, CA, USA</Institution></Header><Header title="Principal Investigators"><AttrName>David A. Hafler, MD</AttrName><Institution>Brigham and Women's Hospital, Boston, MA, USA</Institution></Header><Header title="Principal Investigators"><AttrName>Margaret A. Pericak-Vance, PhD</AttrName><Institution>University Of Miami, Miami, FL, USA</Institution></Header><Header title="Principal Investigators"><AttrName>Jonathan L. Haines, PhD</AttrName><Institution>Vanderbilt University Medical Center, Nashville, TN, USA</Institution></Header><Header title="Principal Investigators"><AttrName>John D. Rioux, Ph.D</AttrName><Institution>Universit&#233; de Montr&#233;al, Montreal, CA</Institution></Header><Header title="Principal Investigators"><AttrName>Stephen Sawcer, MB, ChB, PhD</AttrName><Institution>University of Cambridge School of Clinical Medicine, Cambridge, UK</Institution></Header><Header title="Principal Investigators"><AttrName>Jorge R. Oksenberg, PhD</AttrName><Institution>University of California at San Francisco, CA, USA</Institution></Header><Header title="Principal Investigators"><AttrName>Eric S. Lander, PhD</AttrName><Institution>Broad Institute, Cambridge, MA, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Jacob L. McCauley, PhD</AttrName><Institution>Vanderbilt University Medical Center, Nashville, TN, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Simon G. Gregory, PhD</AttrName><Institution>Duke University Medical Center, Durham, NC, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Mark J. Daly, PhD</AttrName><Institution>Broad Institute, Cambridge, MA, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Philip L. De Jager, MD</AttrName><Institution>Brigham and Women's Hospital, Boston, MA, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Paul I.W. de Bakker, PhD</AttrName><Institution>Broad Institute, Cambridge, MA, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Lisa F. Barcellos, PhD</AttrName><Institution>University of California at Berkeley, Berkeley, CA, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Bruce Cree, MD, PhD</AttrName><Institution>University of California at San Francisco, CA, USA</Institution></Header><Header title="Co-Investigators"><AttrName>Adrian J. Ivinson, PhD</AttrName><Institution>Harvard Medical School, Boston, MA, USA</Institution></Header><Header title="Funding Source"><AttrName>AP-3758-A16</AttrName><Institution>National Multiple Sclerosis Society, New York, NY, USA</Institution></Header><Header title="Funding Source"><AttrName>RG-2899</AttrName><Institution>National Multiple Sclerosis Society, New York, NY, USA</Institution></Header><Header title="Funding Source"><AttrName>CA-1001-A14</AttrName><Institution>National Multiple Sclerosis Society, New York, NY, USA</Institution></Header><Header title="Funding Source"><AttrName>FG-1718-A1</AttrName><Institution>National Multiple Sclerosis Society, New York, NY, USA</Institution></Header><Header title="Funding Source"><AttrName>NS049477</AttrName><Institution>National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA</Institution></Header><Header title="Funding Source"><AttrName>NS032830</AttrName><Institution>National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA</Institution></Header><Header title="Funding Source"><AttrName>NS26799</AttrName><Institution>National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA</Institution></Header><Header title="Funding Source"><AttrName>AI067152</AttrName><Institution>National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA</Institution></Header><Header title="Funding Source"><AttrName>P01-AI039671</AttrName><Institution>National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA</Institution></Header><Header title="Funding Source"><AttrName>76113</AttrName><Institution>Wellcome Trust, London, UK</Institution></Header><Header title="Funding Source"><AttrName>U54-RR020278-1</AttrName><Institution>National Center for Research Resources, Bethesda, MD, USA</Institution></Header><Header title="Funding Source"><AttrName>NS2427</AttrName><Institution>National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA</Institution></Header></Attributions><StudyURLs><Url name="International Multiple Sclerosis Consortium" url="http://www.imsgc.org/"/></StudyURLs><Publications><Publication><Pubmed pmid="17660530"/></Publication><Publication><Unparsed>International Multiple Sclerosis Genetics Consortium, Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, de Bakker PI, Gabriel SB, Mirel DB, Ivinson AJ, Pericak-Vance MA, Gregory SG, Rioux JD, McCauley JL, Haines JL, Barcellos LF, Cree B, Oksenberg JR, Hauser SL. 
Risk alleles for multiple sclerosis identified by a genomewide study. 
N Engl J Med. 2007 Aug 30; 357(9):851-62. </Unparsed></Publication></Publications></StudyInfo><Authority><ICs><IC id="7" name="NINDS" is_funding_ic="false" is_admin_ic="false" primary="true"/></ICs><Persons><Person nedid="HAUSERS" aid="2" auth="eRA" login="HAUSERS" fname="Stephen" mname="L" lname="Hauser" email="stephen.hauser@ucsf.edu"><Role>PI</Role><Organization>UNIVERSITY OF CALIFORNIA, SAN FRANCISCO</Organization></Person><Person nedid="0010563438" aid="1" auth="cit" login="utzu" fname="Ursula" mname="" lname="Utz" email="utzu@ninds.nih.gov"><Role>PO</Role><Organization>NIH</Organization></Person><Person nedid="0013269007" aid="1" auth="cit" login="kianga" fname="Anne" mname="" lname="Sturcke" email="kianga@ncbi.nlm.nih.gov"><Role>PHENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="0010146585" aid="1" auth="cit" login="zhangr" fname="Ran" mname="" lname="Zhang" email="zhangr@mail.nih.gov"><Role>GPA</Role><Organization>NIH</Organization></Person></Persons></Authority><Policy display-research-statement="true" display-public-summary="true" years-until-renewal="1" weeks-to-cancel-request="8" pub-embargo="none"><acknowledgement_statement>INSTRUCTIONS:  This study has not provided a suggested acknowledgement statement. However, Approved Users are expected to acknowledge the Submitting Investigator(s) who submitted data from the original study to an NIH-designated data repository, the primary funding organization that supported the Submitting Investigator(s), and the NIH-designated data repository (e.g., dbGaP).  The acknowledgment statement should include the dbGaP accession number to the specific version of the dataset(s) analyzed.</acknowledgement_statement><DUC universal_duc="Yes"><File full_url="https://dbgap.ncbi.nlm.nih.gov/aa/docs/Static_DUC_20190419.pdf" filename="Static_DUC_20190419.pdf" content-type="application/pdf"/></DUC><DUC_PDF universal_duc="Yes"><File full_url="https://dbgap.ncbi.nlm.nih.gov/aa/docs/Static_DUC_20190419.pdf" filename="Static_DUC_20190419.pdf" content-type="application/pdf"/></DUC_PDF><GSR_Access gsr_mode="unrest_access_by_timeout" gsr_mode_label="Unrestricted access (institution did not respond within six months)"/><ConsentGroup uid="29" CGType="cg_class_other" title="Multiple Sclerosis and Related disorders" name="MSRD" dac_uid="53" dac_name="NINDS" irb-approval-required="No"><Use-Restriction>These data will be used for research purposes only. They will not be used to determine the individual identity of any person nor their relationship to another person. The use of the data is limited to studies of multiple sclerosis and related autoimmune disorders.
</Use-Restriction></ConsentGroup><ConsentGroup uid="30" CGType="cg_class_other" title="Multiple Sclerosis " name="MS" dac_uid="53" dac_name="NINDS" irb-approval-required="No"><Use-Restriction>These data will be used for research purposes only. They will not be used to determine the individual identity of any person nor their relationship to another person. The use of the data is limited only to studies involving multiple sclerosis.</Use-Restriction></ConsentGroup><ConsentGroup uid="31" CGType="cg_class_other" title="Non-Profit Use Only" name="NPU" dac_uid="53" dac_name="NINDS" irb-approval-required="No"><Use-Restriction>These data will be used for research purposes only. They will not be used to determine the individual identity of any person nor their relationship to another person. The informed consent document signed by study participants allows use of these genetic data by investigators employed by non-profit organizations only. Direct use of these data by commercial companies to develop diagnostics or therapeutics is not allowed under the current consent.</Use-Restriction></ConsentGroup></Policy><SRA/><Documents/><Status uid="1" name="released" title="Released"/></Study></dbgapss>